China
Africa
Explore chapters and articles related to this topic
Nonmelanocytic Lesions
Published in Ashfaq A Marghoob, Ralph Braun, Natalia Jaimes, Atlas of Dermoscopy, 2023
Nicole Nagrani, Natalie M. Williams, Natalia Jaimes
Infantile hemangiomas usually become clinically apparent within the first few days to months of life, yet some newborns may show a telangiectatic patch at the hemangioma site as a premonitory sign. These tumors are characterized by rapid growth or proliferation followed by a slow involution stage. Clinically, they appear as bright red to violaceous papules, plaques, or tumors of different sizes. On the other hand, cherry hemangiomas, also known as cherry angiomas or Campbell de Morgan spots, are common cutaneous capillary proliferations that present as small red to violaceous papules in adults. They are commonly found on the trunk and tend to increase in number with age.
Benign Neoplasms
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Abdullah Demirbaş, Ömer Faruk Elmas, Necmettin Akdeniz
Overview: Although its pathogenesis is unclear, the increase in number and size during pregnancy and its disappearance in the postpartum period indicates that hormonal factors may play a role. In addition, a cherry angioma has been reported in women with high serum prolactin levels. Lesions can be seen in both sexes. Some lesions occur in young adulthood, but the incidence gradually increases over the age of 30 years. Originally thought to be paraneoplastic, cherry angiomas are benign.
Benign Nonmelanocytic Skin Tumors
Published in Aimilios Lallas, Zoe Apalla, Elizabeth Lazaridou, Dimitrios Ioannides, Theodosia Gkentsidi, Christina Fotiadou, Theocharis-Nektarios Kirtsios, Eirini Kyrmanidou, Konstantinos Lallas, Chryssoula Papageorgiou, Dermatoscopy A–Z, 2019
Aimilios Lallas, Zoe Apalla, Elizabeth Lazaridou, Dimitrios Ioannides, Theodosia Gkentsidi, Christina Fotiadou, Theocharis-Nektarios Kirtsios, Eirini Kyrmanidou, Konstantinos Lallas, Chryssoula Papageorgiou
Cherry angiomas are very frequently found vascular tumors, dermatoscopically typified by red to purple lacunas (globules), which are well-circumscribed, round to oval structures, histopathologically corresponding to dilated, blood-filled vessels in the papillary dermis. A white veil or white lines are frequently seen among the lacunas (Figure 4.20). Most cherry angiomas are very easy to recognize clinically. A few cherry angiomas might be morphologically equivocal for a macroscopic aspect, and dermatoscopy will usually reveal a lacunar pattern and solve the diagnostic uncertainty (Figure 4.21).
Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent
Published in Acta Oncologica, 2019
Yan Teng, Ruifeng Guo, Jianfang Sun, Yiqun Jiang, Yi Liu
A female in her 70s with a history of stage IV lung adenocarcinoma who was receiving injections of SHR-1210 in a phase II trial (NCT03085069) developed similar findings. Two weeks after the first injection, she developed multiple, 2-5 mm, dome-shaped, bright red papules on her scalp, face, neck, chest, abdomen, and back (Figure 1(B)). The patient remained on SHR-1210 and the lesions increased in both size and number. Histological examination of one lesion from the face revealed dilated vascular channels filled with erythrocytes, located on the upper-mid-dermis, lined by endothelial cells. Based on these clinical and histopathological findings, a diagnosis of eruptive cherry angiomas was made.
Eruptive cherry angiomas developing in a patient treated with ramucirumab
Published in Acta Oncologica, 2018
Pablo Espinosa Lara, Camino Medina-Puente, Alejandro Riquelme Oliveira, José Jiménez-Reyes
Cherry angiomas (CA), also known as senile angiomas or Campbell de Morgan spots, are the most common benign vascular proliferation [4–7]. The term eruptive cherry angiomas (ECA), which involves the sudden and extensive onset of multiple CA, has been rarely reported and its etiopathogenesis has been poorly investigated [4–7]. We report a patient who developed ECA while receiving ramucirumab.